Detalhe da pesquisa
1.
Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer.
Prostate
; 84(1): 100-110, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37796107
2.
Defining the challenges and opportunities for using patient-derived models in prostate cancer research.
Prostate
; 84(7): 623-635, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38450798
3.
Third generation quinoline-3-carboxamide transcriptional disrupter of HDAC4, HIF-1α, and MEF-2 signaling for metastatic castration-resistant prostate cancer.
Prostate
; 83(15): 1470-1493, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37559436
4.
A comparison of prostate cancer cell transcriptomes in 2D monoculture vs 3D xenografts identify consistent gene expression alterations associated with tumor microenvironments.
Prostate
; 80(6): 491-499, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32068909
5.
LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics.
Prostate
; 77(6): 654-671, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28156002
6.
Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates.
NPJ Precis Oncol
; 8(1): 104, 2024 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38760413
7.
Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex.
Cancer Res
; 83(17): 2938-2951, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37352376
8.
Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer.
JCI Insight
; 8(7)2023 04 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36821396
9.
Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers.
Cancer Res Commun
; 3(11): 2358-2374, 2023 11 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37823778
10.
Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes.
Cancer Discov
; 13(3): 632-653, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36399432
11.
Pharmacological NF-κB inhibition decreases cisplatin chemoresistance in muscle-invasive bladder cancer and reduces cisplatin-induced toxicities.
Mol Oncol
; 17(12): 2709-2727, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37533407
12.
ASSESSMENT OF CELL SURFACE TARGETS IN METASTATIC PROSTATE CANCER: EXPRESSION LANDSCAPE AND MOLECULAR CORRELATES.
Res Sq
; 2023 Dec 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38196594
13.
Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases.
Am J Pathol
; 179(1): 400-10, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21703419
14.
Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer.
Clin Cancer Res
; 28(14): 3127-3140, 2022 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35552660
15.
Defining cellular population dynamics at single-cell resolution during prostate cancer progression.
Elife
; 112022 12 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36511483
16.
The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches.
Endocr Relat Cancer
; 28(8): T51-T66, 2021 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33792558
17.
Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature.
PLoS One
; 16(1): e0245602, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33471819
18.
Multiplexed functional genomic analysis of 5' untranslated region mutations across the spectrum of prostate cancer.
Nat Commun
; 12(1): 4217, 2021 07 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34244513
19.
Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth.
J Clin Invest
; 131(10)2021 05 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-33998604
20.
Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer.
JCI Insight
; 6(8)2021 04 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-33724955